ArticleClinical rheumatology2021
Gastrointestinal involvement in IgA vasculitis: a single-center 11-year study on a cohort of 118 children.
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Guidelines for the diagnosis and management of childhood immunoglobulin A vasculitis.World journal of pediatrics : WJP · 2025Guideline
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Abdominal pain in pediatric immunoglobulin A vasculitis: Risk factors and severity predictors in a multicenter cohort.Journal of pediatric gastroenterology and nutrition · 2026Article
- Factors predicting the severity of gastrointestinal involvement in children with IgA vasculitis? A Turkish multicenter cohort study.European journal of pediatrics · 2026Article
- Article
- Clinical characteristics and differential diagnosis model of IgAV with gastrointestinal symptoms and acute abdominal disease: an observational controlled study.Frontiers in immunology · 2026Observational
- Atypical presentation of immunoglobulin A vasculitis mimicking acute appendicitis in a pediatric patient: a case report.Future science OA · 2025Article
- Article
- Clinical review of adult Henoch-Schönlein purpura and analysis of predictors related to gastrointestinal involvement.Frontiers in immunology · 2025Article
- Terminal ileitis: a rare gastrointestinal manifestation of IgA vasculitis in a child.BMJ case reports · 2024Article
- Multidrug-resistant IgA Vasculitis with Gastrointestinal Symptoms Successfully Treated with Intravenous Cyclophosphamide and Maintained with Mycophenolate Mofetil.Internal medicine (Tokyo, Japan) · 2024Article
- Gastrointestinal manifestations and pathogenesis in childhood immunoglobulin A vasculitis.Frontiers in pediatrics · 2024Review
- Delayed diagnosis of abdominal Henoch-Schonlein purpura in children: A case report.World journal of clinical cases · 2023Article
- Intravenous immunoglobulin therapy in immunoglobulin A vasculitis with gastrointestinal tract involvement.Clinical and experimental medicine · 2023Article
- Severe gastrointestinal involvement in pediatric IgA vasculitis: a retrospective single-center cohort study in China.Frontiers in pediatrics · 2023Article
- Blood routine examination: a simple way for differential diagnosis of immunoglobulin A vasculitis with abdominal involvement and appendicitis in children.Updates in surgery · 2022Article
- Serum Syndecan-1 levels in patients with immunoglobulin A vasculitis in children.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectivesImmunoglobulin A vasculitis (IgAV), the most common childhood vasculitis, is associated with gastrointestinal (GI) involvement in 50-75% of cases. The aim of this study was to describe the characteristics of GI involvement in a cohort of hospitalized children with IgAV.
methodsWe retrospectively evaluated patients hospitalized for IgAV at Meyer Children's University Hospital, from January 2010 to December 2020. The children's families were interviewed by phone and asked about disease relapses.
resultsIn the study period, 118 children had GI involvement, corresponding to 75% of children hospitalized for IgAV. Their median age was 7 years (interquartile range 6-9). The most frequent GI manifestations were abdominal pain (96%), bleeding (71%, mostly occult), vomiting (58%), and diarrhea (17%). GI complications, observed in 18%, were intussusception (14%), appendicitis (3%), gallbladder hydrops (2%), and ileal perforation (1%). Abdomen ultrasound, performed in all cases, was abnormal in 68%. Abdomen X-ray, performed in 19 patients, showed pathologic findings in 84% of them. Selected children with severe manifestations also underwent abdomen computed tomography (2/118; 2%) and GI endoscopy (5/118; 4%). Steroids were used in 80 (67.8%) cases. The use of second- and third-line therapies was necessary in three cases. Relapses, investigated in 80 cases (68%), occurred in 21% of them. Key Points • The present retrospective study describes a cohort of 118 patients hospitalized for gastrointestinal (GI) involvement in immunoglobulin A vasculitis (IgAV) at a tertiary care children's hospital from January 2010 to December 2020. • The most frequent GI manifestations were abdominal pain (96%), vomiting (58%), and diarrhea (17%). GI bleeding was reported in 71% of children, and it was occult in most cases. • GI complications, occurring in 18% of cases, were intussusception (14%), appendicitis (3%), gallbladder hydrops (2%), and ileal perforation (1%). • Steroid treatment has been successfully used in severe GI manifestations; however, our data do not support its association with low relapse risk.
conclusionsThe present study describes a large pediatric cohort of GI involvement in IgAV. Steroid treatment should be used when GI manifestations are severe. The association of steroid use with relapse risk is not currently established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.